October 29, 2024
| Trial | CV6-168 combination Phase I/IIa trial |
|---|---|
| Cancer Type | Miscellaneous and Non-specific |
| Hospital(s) | Belfast City Hospital |
| Information | CV6-168 – A First in Human Modular, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of the specific dUTPase inhibitor CV6-168 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies |